Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor in Combination With the Proteasome Inhibitor Ixazomib for the Treatment of Advanced Sarcoma

NCT03880123 is registered in ClinicalTrials.gov with Matthew Ingham as lead sponsor.

NCT NCT03880123
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03880123 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor in Combination With the Proteasome Inhibitor Ixazomib for the Treatment of Advanced Sarcoma
Lead sponsor
Matthew Ingham
Phase
Phase 1
Overall status
Withdrawn
Start date
November 30, 2020
Completion date
November 24, 2020
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alveolar soft part sarcoma, ewing sarcoma, liposarcoma, malignant peripheral nerve sheath tumors, sarcoma